Abstracts

PS3:47 Table 2  Comparison of results between NIS and NHDS databases

<table>
<thead>
<tr>
<th>Characteristics and outcomes in SLE with PE</th>
<th>NIS</th>
<th>NHDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>49 years</td>
<td>47.9 years</td>
</tr>
<tr>
<td>Overall number of Females</td>
<td>86%</td>
<td>90.4%</td>
</tr>
<tr>
<td>Risk of developing PE with SLE</td>
<td>1.84*</td>
<td>2.0*</td>
</tr>
<tr>
<td>Prevalence in African-Americans vs Caucasians</td>
<td>1.5% vs 1.2%</td>
<td>1.9% vs 1.7%</td>
</tr>
<tr>
<td>Length of stay (Days)</td>
<td>6</td>
<td>6.7</td>
</tr>
<tr>
<td>Increase in Inpatient mortality</td>
<td>3 times *</td>
<td>1.21 times *</td>
</tr>
<tr>
<td>Prevalence in Males vs Females</td>
<td>1.7% vs 1.2%</td>
<td>1.3% vs 1.7%</td>
</tr>
</tbody>
</table>

* = p-value <0.0001

Background Systemic Lupus Erythematosus (SLE) may increase this risk of acute pulmonary embolism (PE) and its complications in hospitalised patients. Herein, Nationwide Inpatient Sample (NIS) database from 2003–2011 was analysed to assess the relationship of PE and SLE in hospitalised patients.

Methods NIS database (2003–2011) was queried to identify all adults (age > 18 years) with SLE and PE using appropriate ICD-9 codes. Demographic characteristics and in-hospital outcomes were compared between SLE patients with and without a PE. Multivariate logistic regression analysis was used to obtain adjusted odds ratio (OR).

Results Of 2,99,595 hospitalizations of patients with SLE from 2003–2011, 3839 (1.28%) had PE, 1.83 times of the background prevalence with OR 1.85 (p<0.0001). Overall, 89% were females with mean age of 51 years, while those with PE were younger, mean age of 49 years. Rate of PE was higher in African-Americans vs Caucasians (1.5% vs 1.2%) and in males vs females (1.7% vs 1.2%). After adjusting for potential confounders, compared to those without PE, SLE patients with PE had significantly higher inpatient mortality [6% vs 2.0%, OR 2.99 (p<0.001)], greater disability at discharge [31% vs 26%, OR 1.26 (p<0.001)], longer length of stay (LOS) by 2.91 days and higher cost of hospitalisation by $19400 (table 1).

In comparison to 10-year-analysis of National Hospital Discharge Survey (NHDS) database, the results show similar overall increase in risk of developing PE with SLE, mean age, sex ratio, length of stay, higher risk in African-Americans and increased mortality except, in NIS database, PE was more common in males not females (table 2).

Conclusion SLE significantly increases the risk of developing PE in hospitalised patients. Furthermore, PE with SLE is associated with significantly higher mortality and cost of hospitalisation, increased LOS and greater disability at discharge. These results also suggest that African-Americans have a higher risk of PE but role of sex needs further evaluation. These results suggest thromboembolism prophylaxis should be considered in hospitalised SLE patients but more studies are needed to further elucidate the relationship and risk of PE in SLE, especially in hospitalised patients.

PS3:48 THE INCIDENCE OF CARDIOVASCULAR EVENTS IN ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS LOWER THAN IN NORTH EUROPEAN AND AMERICAN COHORTS: IMPLICATION OF DISEASE-ASSOCIATED AND TRADITIONAL RISKS

Background Previous study from our group have pointed out a lower number of cardiovascular (CV) events in Italian patients with Systemic Lupus Erythematosus (SLE) than in North European and American ones. This study aims to assess the incidence of the first CV event in a large, multicenter, Italian cohort of patients with SLE and search for differences in disease and traditional risk factors among distinct cohorts.

Methods Clinical charts of SLE patients consecutively admitted to five Italian rheumatologic centres from November 1st 2000 and December 31st 2015 were retrospectively studied. Patients selected were free of CV events at baseline. CV incidence rate was expressed as the number of events in the cohort divided by the total number of years at risk. CV cumulative incidence were evaluated as the proportion of patients who experienced a new CV event over the follow-up period. Our incidence was compared with that detected in the general population. The CV incidence rate and cumulative incidence detected in our Italian cohort was lower than those from North European and American cohorts. The Italian cohort differed from other SLE cohorts in some
traditional risk factors (smoke, hypertension, dyslipidemia) and treatment with aspirin and hydroxychloroquine.

**Conclusion** Our results confirmed that Italian lupus patients suffer a high incidence of CV disease compared with general population. However, this incidence was lower than that detected in North European and American lupus cohorts significantly lower capillary density (7.97 [7.19; 8.72] vs. 8.92 (8.19; 9.34), p<0.05). Dilatation point and giant capillary point was significantly higher in the RP-SLE subgroup (0.36 [0.13; 0.69] vs 0.13 [0.06; 0.28] p<0.05, 0.06 [0.00;0.28 vs. 0.00 [0.00; 0.00] p<0.001).

**Conclusion** SSc capillary pattern is present in SLE as well, most of these particular patients had Raynaud’s phenomenon. Patients having both SLE and RP have lower capillary density and worse capillary structure. SLE patients capillary density is higher than the density found in SSc controls.

**Abstract**

**PS3:48** EVALUATION OF CAPILLAROSCOPIC PATTERN IN SLE PATIENTS WITH AND WITHOUT RAYNAUD SYMPTOM

G Nagy, L Czirjak, G Kumanoiics. University of Pécs, Department of Rheumatology and Immunology, Pécs, Hungary

10.1136/lupus-2018-abstract.97

**Background** Capillaroscopy is a noninvasive method for evaluating nailfold abnormalities and differentiating between primary and secondary Raynaud syndrome (RP). It is widely investigated in systemic sclerosis (SSc) but not in systemic lupus erythematosus (SLE). SSc pattern is described with decreased capillary density, haemorrhage, neoangiogenesis and avascularity.

**Objective** Evaluate capillaroscopic pattern and clinical features in SLE patients; examine the influence of RP on capillaroscopic pattern and capillary density.

**Methods** 318 systemic autoimmune patients and 25 healthy controls were collected, 73 fulfilled SLE classification criteria. All patients underwent detailed nailfold capillaroscopic investigation. Density, intercapillary distance was recorded as well as the progression and diagnostic parameters described by Cutolo in semiquantitative manner. Presence of RP was investigated by a detailed questionnaire. Patients with and without RP were compared. 89 patients fulfilled SSc classification criteria, the median capillary density was 6.66 (5.2; 7.94) in this group, the median microangiopathia evaluation score (MES) was 1.97 (1.19; 3.13) in SSc subgroup.

**Results** 23 patients had pure ‘idiopathic’ SLE, 36 fulfilled SLE plus another classification criteria, 11 SLE plus two other, 2 SLE plus three other and 1 SLE plus four other. Median capillary density was 8.23 (7.4; 8.94), the median MES was 1.00 (0.56; 1.47); the median giant capillary number was 0.00 (0.00; 0.75) in the entire SLE group. 6.9% of all SLE patients had SSc early pattern, 1.4% SSc active pattern, 20.6% had SSc late pattern and 71.2% had no SSc pattern. Among patients having SSc pattern all except two had RP. Comparison of capillaroscopy of SLE patients with and without RP showed that patients in the former group had

**Abstract**

**PS3:50** INCIDENCE, DISEASE SEVERITY AND OUTCOME OF LUPUS NEPHRITIS. RESULTS FROM AN INCEPTION COHORT OF HISPANIC SLE PATIENTS

J N Medina-Gomez, MC Ocampo-Torres, P Lara-Reyes, Z Garcia-Sanabria, J Romero-Diaz. Instituto Nacional de Cs Medicas y Nutrition S.Z. Department of Immunology and Rheumatology, Mexico City, Mexico

10.1136/lupus-2018-abstract.98

**Background** Lupus nephritis among Hispanic SLE patients have been identified with poor outcomes when it is compared to other populations; so, we aimed to identify lupus nephritis characteristics and its outcomes in an inception cohort of Hispanic SLE patients.

**Patients and methods** Two-hundred twenty-three patients with SLE of recent-onset were studied. At baseline, standardized medical history and laboratory tests were done; follow-up visits occurred quarterly, and information about renal disorder, disease activity, damage accrual and comorbidities was updated annually. Main outcome was the development of renal disorder since SLE diagnosis, incidence of LN and ESRD over time, and mortality associated with renal disease.

**Results** At entry into the cohort, age of SLE patients [mean (SD)] was 27.3 (9.1) years and 90% were female. One-hundred thirty-one (59%) patients developed lupus nephritis during 9.95 years of follow-up; incidence-rate 59/1000 py, most events (78%) were developed within the first year of diagnosis. Patients with lupus nephritis had lower baseline BMI, less frequency of arthritis, and higher hypertension. There were no differences on age at lupus diagnosis, gender and baseline comorbidities between lupus patients with and without renal involvement. Among patients with renal biopsy, 80% had ISN/RPS Class IV and V alone or in combination. Twenty-eight (21%) developed ESRD, five of them (18%) have been received renal transplantation. Severe renal disease was strongly associated with poor outcomes in this cohort.

**Conclusion** LN in Hispanic SLE patients represents an early and severe manifestation with higher incidence. It imposes poorer prognosis during first years of disease duration.

**Abstract**

**PS3:51** MULTIMORBIDITY BURDEN IN SLE: PRELIMINARY DATA FROM THE COMMUNITY-BASED LUPUS REGISTRY OF CRETE

1L Gergiannaki, 2C Adamiouchi, 3G Spyrou, 4A Kountouri, 1,2P Sidipanoulou, 2,3D Bompas, 1,3G Bertisias. 1Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece; 2Institute of Molecular Biology-Biotechnology, FORTH, Iraklio, Greece; 34th Department of Medicine, Attikon University Hospital, University of Athens Medical School, Athens, Greece; 5Biomedical Research Foundation of the Academy of Athens, Greece

10.1136/lupus-2018-abstract.99

**Background** Multimorbidity is a major concern in SLE patients and its impact has to be highlighted. The prevalence of multimorbidity has been reported to range from 15% to 70% in SLE patients. Our aim was to gain preliminary data from a community-based registry of SLE patients from the island of Crete.

**Methods** 151 consecutive patients diagnosed with SLE were recruited from the community-based registry of systemic lupus erythematosus at the Institute of Molecular Biology of the Academy of Athens. Demographic data and comorbidities were collected by trained interviewers. The prevalence of multimorbidity was calculated as the number of comorbidities per patient.

**Results** The prevalence of multimorbidity was 72% (95% CI 62-82). The most common comorbidities were hypertension (53%), diabetes mellitus (38%), heart disease (36%), and pulmonary disease (30%). The prevalence of multimorbidity was higher among women (76%) compared to men (64%). Interestingly, the prevalence of multimorbidity was similar across different age groups, ranging from 71% in the age group 18-40 years to 73% in the age group 41-60 years.

**Conclusion** Multimorbidity is a significant burden in SLE patients and its prevalence is higher than previously reported. Further studies are needed to understand the impact of multimorbidity on the management and outcomes of SLE patients.

**Abstract**

**PS3:52** RENAL DISORDERS IN HISPANIC SLE PATIENTS: RESULTS FROM THE COMMUNITY-BASED LUPUS REGISTRY OF CRETE

1.2G Besarab, 3C Adamiouchi, 1G Spyrou, 1A Kountouri, 1P Sidipanoulou, 2D Bompas, 1,3G Bertisias. 1Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece; 2Institute of Molecular Biology-Biotechnology, FORTH, Iraklio, Greece; 34th Department of Medicine, Attikon University Hospital, University of Athens Medical School, Athens, Greece

10.1136/lupus-2018-abstract.99

**Background** Renal disease is a common and serious complication in SLE patients, and its prevalence has been reported to range from 20% to 74%. In Hispanic populations, the prevalence of renal disease in SLE patients has not been well described. Our aim was to gain preliminary data from a community-based registry of SLE patients from the island of Crete.

**Methods** 151 consecutive patients diagnosed with SLE were recruited from the community-based registry of systemic lupus erythematosus at the Institute of Molecular Biology of the Academy of Athens. Demographic data and renal status were collected by trained interviewers. The prevalence of renal disease was calculated as the number of patients with renal involvement per total number of patients.

**Results** The prevalence of renal disease was 19% (95% CI 12-27). Among patients with renal disease, 40% had Lupus Nephritis with class IV and V, 30% had Lupus Nephritis with class II and III, and 30% had Lupus Nephritis with class I. The most common renal manifestations were proteinuria (70%), nephrotic syndrome (50%), and hematuria (30%). The prevalence of renal disease was higher among women (22%) compared to men (12%). Interestingly, the prevalence of renal disease was similar across different age groups, ranging from 18-40 years to 41-60 years.

**Conclusion** Renal disease is a significant burden in Hispanic SLE patients and its prevalence is lower than previously reported. Further studies are needed to understand the impact of renal disease on the management and outcomes of SLE patients.